
Please try another search
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on uniQure (NASDAQ:QURE) N.V. on Thursday, setting a price target of $95, which is approximately 230.43% above the present share price of $28.75.
Livshits expects uniQure N.V. to post earnings per share (EPS) of -$0.79 for the fourth quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in uniQure, with an average price target of $56.8.
The analysts price targets range from a high of $66 to a low of $46.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $1.99 million and a net profit of -$45 million. The company's market cap is $1.33 billion.
According to TipRanks.com, Chardan Capital analyst Geulah Livshits is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 51.7% and a 51.64% success rate.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.